Psoriasis Clinical Trial

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Summary

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
Have venous access sufficient to allow for blood sampling
Are able to swallow oral medication
Agree to skin biopsies

Exclusion Criteria:

Have any other skin conditions, excluding plaque psoriasis
Have a current or recent acute, active infection
Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
Are lactating or breastfeeding women

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

75

Study ID:

NCT06176768

Recruitment Status:

Recruiting

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Dermatology Research Associates
Los Angeles California, 90045, United States More Info
Howard Sofen
Principal Investigator
Clinical Science Institute
Santa Monica California, 90404, United States More Info
Paul Yamauchi
Principal Investigator
Driven Research
Coral Gables Florida, 33134, United States More Info
Javier Alonso-Llamazares
Principal Investigator
Conquest Research
Winter Park Florida, 32789, United States More Info
Contact
407-916-0060
Malisa Agard
Principal Investigator
Psoriasis Treatment Center of Central New Jersey
East Windsor New Jersey, 08520, United States More Info
Contact
609-443-4500
Jerry Bagel
Principal Investigator
Metropolitan Dermatology - Clark
Kenilworth New Jersey, 07033, United States More Info
Alexander Doctoroff
Principal Investigator
Accellacare - Winston-Salem
Winston-Salem North Carolina, 27103, United States More Info
Contact
336-768-8062
Christine Yuengel-Bienenfeld
Principal Investigator
DermDox Centers for Dermatology
Camp Hill Pennsylvania, 17011, United States More Info
Stephen M. Schleicher
Principal Investigator
Center for Clinical Studies
Houston Texas, 77004, United States More Info
Contact
713-528-8818
Stephen Keith Tyring
Principal Investigator
Austin Institute for Clinical Research
Houston Texas, 77056, United States More Info
Megan Poynot Couvillion
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

75

Study ID:

NCT06176768

Recruitment Status:

Recruiting

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.